pregabalin
Adjunctive therapy • Brands: LYRICA, LYRICA CR
Last reviewed: 2025-12-29
General information
- Primary label indications include: Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury); fibromyalgia; adjunctive therapy for partial-onset seizures (label).
- Class: Adjunctive therapy
- Common US brands: LYRICA, LYRICA CR
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-29
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Alpha-2-delta (α2δ) ligand that modulates voltage-gated calcium channels and reduces excitatory neurotransmitter release.
Metabolism & Half‑life
- Metabolism: Negligible metabolism; eliminated primarily unchanged (label).
- Half‑life: Single-dose mean 6.3 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Pregabalin prescribing information (Lyrica) — DailyMed (2025)
- Gabapentin and Pregabalin for the Treatment of Anxiety Disorders — Clinical Pharmacology in Drug Development (2018)
- A Meta-Analysis of the Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder — The Canadian Journal of Psychiatry (2011)
- Pregabalin for generalized anxiety disorder — International Clinical Psychopharmacology (2017)
- Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update — Drugs (2021)